PD-L1 Protein, Human, Recombinant (ECD, His Tag)
Cat: 10084-H08H
PD-L1 Protein, Human, Recombinant (ECD, His Tag): Product Information
Purity
> 98 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
1. Measured by its binding ability in a functional ELISA. Immobilized human B7-H1 at 20 μg/ml (100 μl/well) can bind human PD1 with a linear range of 0.032-0.8 μg/ml.
2. Using the Octet RED System, the affinity constant (Kd) of PD-1 Protein, Human, Recombinant (Fc Tag) (Cat. 10377-H02H) bound PD-L1 Protein, Human, Recombinant (His Tag) (Cat. 10084-H08H) was 19.2nM.
2. Using the Octet RED System, the affinity constant (Kd) of PD-1 Protein, Human, Recombinant (Fc Tag) (Cat. 10377-H02H) bound PD-L1 Protein, Human, Recombinant (His Tag) (Cat. 10084-H08H) was 19.2nM.
Protein Construction
A DNA sequence encoding the N-terminal segment (Met 1-Thr 239) of the extracellular domain of human B7-H1 (NP_054862.1) was expressed with a C-terminal polyhistidine tag.
Accession#
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Phe 19
Molecule Mass
The recombinant mature human B7-H1 comprises 232 amino acids and predicts a molecular mass of 26.8 kDa. As a result of glycosylation, the human B7-H1 migrates as an approximately 35-38 kDa protein in SDS-PAGE under reducing conditions.
Formulation
Lyophilized from sterile PBS, pH 7.4
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
PD-L1 Protein, Human, Recombinant (ECD, His Tag): Images
Measured by its binding ability in a functional ELISA. Immobilized human B7-H1 at 20 μg/ml (100 μl/well) can bind human PD1 with a linear ranger of 0.032-0.8 μg/ml.
PD-L1 Protein, Human, Recombinant (ECD, His Tag): Synonyms
B7-H Protein, Human; B7-H1 Protein, Human; B7H1 Protein, Human; PD-L1 Protein, Human; PDCD1L1 Protein, Human; PDCD1LG1 Protein, Human; PDL1 Protein, Human
PD-L1 Background Information
Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
- Cancer Immunotherapy
- Co-inhibitory Immune Checkpoint Targets
- Immune Checkpoint
- Immune Checkpoint Blockade: Blocking Antibodi
- Immune Checkpoint Blockade: PD-L1 / B7-H1 / C
- Immune Checkpoint Detection: Antibodies
- Immune Checkpoint Detection: ELISA Antibodies
- Immune Checkpoint Detection: FCM Antibodies
- Immune Checkpoint Detection: ICC Antibodies
- Immune Checkpoint Detection: IHC Antibodies
- Immune Checkpoint Detection: WB Antibodies
- Immune Checkpoint Proteins
- Immune Checkpoint Targets
- Immunotherapy
- PD-L1 / B7-H1 / CD274 Immune Checkpoint Prote
- Targeted Therapy
Full Name
CD274 molecule
Research Areas
References
- Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
- Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
- Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
- Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
- Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.
Human PD-L1 Proteins
-
Design, isolation and evaluation of the binding efficiency of a DNA aptamer against interleukin 2 receptor alpha, in vitroAuthorShahdordizadeh, M;Taghdisi, SM;Sankian, M;Ramezani, M;Abnous, K;Year2017JournalInt. Immunopharmacol.
-
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracersAuthorBroos, K;Keyaerts, M;Lecocq, Q;Renmans, D;Nguyen, T;Escors, D;Liston, A;Raes, G;Breckpot, K;Devoogdt, N;Year2017JournalOncotarget
-
Novel Humanized Monoclonal Antibodies to PD-L1AuthorSimonetti, M;Alton, K;Shimkets, R;Year2017JournalAbeome Intelligent Antibody DiscoveryApplicationanimal-based
-
Selection of DNA aptamers against Mycobacterium tuberculosis Ag85A, and its application in a graphene oxide-based fluorometric assayAuthorAnsari, N;Ghazvini, K;Ramezani, M;Year2018JournalMicrochimica Acta
-
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppressionAuthorMahoney, KM;Shukla, SA;Patsoukis, N;Chaudhri, A;Browne, EP;Arazi, A;Eisenhaure, TM;Pendergraft, WF;Hua, P;Pham, HC;Bu, X;Zhu, B;Hacohen, N;Fritsch, EF;Boussiotis, VA;Wu, CJ;Freeman, GJ;Year2018JournalCancer Immunol. Immunother.ApplicationSDS-PAGE and WB (control)
-
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 PathwaysAuthorZhao, Y;Lee, CK;Lin, CH;Gassen, RB;Xu, X;Huang, Z;Xiao, C;Bonorino, C;Lu, LF;Bui, JD;Hui, E;Year2019JournalImmunity
-
靶向 PD-1 的多肽阻断剂的设计及评价Author全丽娜, ;刁妍妍, ;李巧, ;李文杰, ;Year2020Journal华东理工大学学报ApplicationSPR
-
PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2AuthorXu, X;Hou, B;Fulzele, A;Masubuchi, T;Zhao, Y;Wu, Z;Hu, Y;Jiang, Y;Ma, Y;Wang, H;Bennett, EJ;Fu, G;Hui, E;Year2020JournalJ. Cell Biol.
If you couldn't find the specific citation, you can:
